Antipsychotic Drugs Market (By Therapeutic Class: First Generation, Second Generation, Third Generation; By Disease: schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases; By Drug: Risperidone, Quetiapine, Olanzapine, Aripiprazole, Others; By Distribution Channel: Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Antipsychotic Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Antipsychotic Drugs Market, by Therapeutic Class, 2024-2033
8.1.1. First Generation
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Second Generation
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Third Generation
8.1.3.1. Market Revenue and Forecast (2021-2033)
9.1. Antipsychotic Drugs Market, by Disease, 2024-2033
9.1.1. Schizophrenia
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Bipolar Disorder
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Unipolar Depression
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Dementia
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Other Diseases
9.1.5.1. Market Revenue and Forecast (2021-2033)
10.1. Antipsychotic Drugs Market, by Drug, 2024-2033
10.1.1. Risperidone
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Quetiapine
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Olanzapine
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Aripiprazole
10.1.4.1. Market Revenue and Forecast (2021-2033)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2021-2033)
11.1. Antipsychotic Drugs Market, by Distribution Channel, 2024-2033
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Drug Stores & Retail Pharmacies
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast (2021-2033)
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.1.2. Market Revenue and Forecast, by Disease (2021-2033)
12.1.3. Market Revenue and Forecast, by Drug (2021-2033)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Disease (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Drug (2021-2033)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Disease (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Drug (2021-2033)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.2.2. Market Revenue and Forecast, by Disease (2021-2033)
12.2.3. Market Revenue and Forecast, by Drug (2021-2033)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Disease (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Drug (2021-2033)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Disease (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Drug (2021-2033)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Disease (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Drug (2021-2033)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Disease (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Drug (2021-2033)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.3.2. Market Revenue and Forecast, by Disease (2021-2033)
12.3.3. Market Revenue and Forecast, by Drug (2021-2033)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Disease (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Drug (2021-2033)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Disease (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Drug (2021-2033)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Disease (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Drug (2021-2033)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Disease (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Drug (2021-2033)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.4.2. Market Revenue and Forecast, by Disease (2021-2033)
12.4.3. Market Revenue and Forecast, by Drug (2021-2033)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Disease (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Drug (2021-2033)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Disease (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Drug (2021-2033)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Disease (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Drug (2021-2033)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Disease (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Drug (2021-2033)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.5.2. Market Revenue and Forecast, by Disease (2021-2033)
12.5.3. Market Revenue and Forecast, by Drug (2021-2033)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Disease (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Drug (2021-2033)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Disease (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Drug (2021-2033)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)
13.1. Eli Lily and Company
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. AstraZeneca plc
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. GlaxoSmithKline plc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Johnson & Johnson
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Otsuka Pharmaceutical Co, Ltd.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Pfizer Inc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. AbbVie Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Bristol-Myers Squibb
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Teva Pharmaceuticals
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Dr. Reddy's Laboratories
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample